专利号:WO-2014057495-A1 优先权日:2012-10-11 标 题 :A process for industrial preparation of [(s)-n-tert butoxycarbonyl-3-hydroxy]adamantylglycine 发明人:ALLA VENKAT REDDY; ALLA RAGHU MITRA; DUBEY AJAY KUMAR; REDDY P RAMAKRISHNA 权利人:LEE PHARMA LTD; ALLA VENKAT REDDY; ALLA RAGHU MITRA; DUBEY AJAY KUMAR; REDDY P RAMAKRISHNA 摘要:A commercially viable process for industrial preparation of [(S)-n-tert butoxycarbonyl-3-hydroxy]adamantylglycine which is a key intermediate for saxagliptin synthesis and is represented by compound of Formula-VI. The compound-VI obtained by the process of present invention has more than 99.5% HPLC purity, not more than 0.15 % of dihydroxy impurity, not more than 0.05% of isomer impurity and not more than 0.1% of any unknown impurity. Formula (VI).
专利号:IT-MI20130132-A1 优先权日:2013-01-30 标题:PROCEDURE FOR THE PREPARATION OF INTERMEDIATES OF SAXAGLIPTINA SYNTHESIS AND NEW COMPOUNDS
1: Toth PP. Overview of saxagliptin efficacy and safety in patients with type 2 diabetes and cardiovascular disease or risk factors for cardiovascular disease. Vasc Health Risk Manag. 2014 Dec 23;11:9-23. eCollection 2015. Review. 2: Konya H, Yano Y, Matsutani S, Tsunoda T, Ikawa T, Kusunoki Y, Matsuo T, Miuchi M, Katsuno T, Hamaguchi T, Miyagawa J, Namba M. Profile of saxagliptin in the treatment of type 2 diabetes: focus on Japanese patients. Ther Clin Risk Manag. 2014 Jul 11;10:547-58. doi: 10.2147/TCRM.S46076. eCollection 2014. Review. 3: Panagoulias GS, Doupis J. Clinical utility in the treatment of type 2 diabetes with the saxagliptin/metformin fixed combination. Patient Prefer Adherence. 2014 Feb 15;8:227-36. doi: 10.2147/PPA.S34089. eCollection 2014. Review.
合成参考文献
参考文献:10.1016/j.ejmech.2024.116464 摘要:Shao D, Zhao L, Sun J. Synthesis and clinical application of representative small-molecule dipeptidyl Peptidase-4 (DPP-4) inhibitors for the treatment of type 2 diabetes mellitus (T2DM). European Journal of Medicinal Chemistry. 2024 Jun;272():116464. doi: 10.1016/j.ejmech.2024.116464.